Drug intelligence / Profile preview

68Ga-GSI

Development stage: Preclinical
Lead developer: Fudan University Shanghai Cancer Center
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

68Ga-GSI is a radiopharmaceutical designed as a positron emission tomography/computed tomography (PET/CT) probe. It targets Granzyme B (GzmB), a protein involved in the immune response. This diagnostic agent is being developed to evaluate early tumor responses to immunotherapy, particularly immune checkpoint inhibitors, by reflecting the immune activation state within tumors. It is currently under clinical investigation for various cancers, including gastric cancer, esophageal cancer, and non-small cell lung cancer.

Targets

GZMB (Granzyme B)

Beyond the preview

Go deeper on 68Ga-GSI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-GSI.

Explore the full profile